The study looked at patients with leukaemia, which occurs in bone marrow, and lymphoma, which affects the lymphatic system.

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company ...

Adults taking the novel once-daily oral pill for plaque psoriasis had significantly higher rates of clear or almost clear ...

AstraZeneca, headquartered in Cambridge, could pay up to $1 billion on a cash and debt-free basis for Belgian company ...

The trial’s primary objective is to assess PALI-2108’s tolerability, pharmacokinetics and safety in healthy volunteers.

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...

Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the U.S., the release ...

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...

It’s not about you, it’s about me.” You’ve heard it a million times, and it’s true. Here’s how to feel good about it.

FILSPARI REMS: Due to the risk of hepatotoxicity and embryo-fetal toxicity, FILSPARI is available only through a restricted program called the FILSPARI REMS. Prescribers, patients, and pharmacies must ...